OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMA
- Sponsors Novartis
- 27 Nov 2016 Status changed from active, no longer recruiting to completed.
- 16 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Nov 2016.
- 16 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2016.